|
**Overview**: Maternal Screen 4 Quadruple Panel**Introduction**: The Maternal Screen 4 Quadruple Panel is a diagnostic tool designed to screen for fetal abnormalities using serum samples. In India, quadruple screening (AFP + free beta-hCG + estriol + inhibin A) in second trimester detects ~80-85 percent of Down syndrome and ~80 percent of open NTDs, improving on triple test. High morbidity from under-screening in rural/low-SES pregnancies, limited labs, delayed detection leading to late diagnosis or birth of affected infant. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society of Perinatology guidelines, the test employs immunoassay for AFP, free beta-hCG, estriol, inhibin A, and risk assessment over 1-2 days with high accuracy, valuable for 15-22 weeks gestation. This diagnostic falls under prenatal screening and targets women without first-trimester screening or high-risk pregnancies, addressing accurate detection to guide amniocentesis or detailed scan. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling improved risk stratification and reducing birth defects burden. Its serum-based approach ensures reliable multi-marker profiling.**Other Names**: Mat Scr 4 Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Quad marker standard since 2000s; in India, used in high-risk antenatal care.**Purpose**: The test assesses 5 parameters including AFP to guide fetal abnormality screening, calculate trisomy/NTD risk, inform diagnostic testing.**Test Parameters**: 1. AFP, 2. Free Beta-hCG, 3. Estriol, 4. Inhibin A, 5. Risk Assessment.**Pretest Condition**: No fasting required; patients should be 15-22 weeks gestation.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, prior screening.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of false-positive/negative including anxiety or missed diagnosis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate risk using appropriate algorithms within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect gestational age can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High risk indicates need for amniocentesis/ultrasound, necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists should be consulted for management.**Additional Supporting Tests**: Level II ultrasound, amniocentesis for confirmation.**Test Limitations**: Screening only (not diagnostic); comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Prenatal Studies India 2023. |
